Yet as the dust settles from the introduction of adalimumab biosimilars following Humira's (AbbVie) patent expiration at long last, it’s clear that formularies have become one of the biggest barriers to realizing the cost-saving potential of biosimilars. Branded drug makers use rebates and marketing strategies to maintain market share, even when lower cost biosimilars are available. THE CONSEQUENCES OF INACTIONThe slow pace of change in formulary strategies and the reluctance to pivot quickly to biosimilars has had real-world consequences. Accessed September 23, 2024. https://www.managedhealthcareexecutive.com/view/express-scripts-to-remove-humira-from-commercial-formularies7. Accessed September 23, 2024. https://www.reuters.com/business/healthcare-pharmaceuticals/unitedhealth-remove-abbvies-humira-some-us-drug-reimbursement-lists-next-year-2024-09-10/

Source: Forbes October 07, 2024 13:33 UTC